Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.62 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8702006 | 0.79 | CES2 (0.62) | RAB9APTPN2PTPN1PTPN6PTPN11 | |
| SCHEMBL9547521 | 0.79 | SMN1; SMN2 (0.56) | RAB9APTPN2PTPN1PTPN6PTPN11 | |
| SCHEMBL2997673 | 0.78 | RAB9A (1.00) | RAB9APTPN2PTPN1PTPN6PTPN11 | |
| SCHEMBL18920602 | 0.78 | SMN1; SMN2 (0.72) | RAB9APTPN1SMN1; SMN2NPC1TP53 | |
| SCHEMBL23011774 | 0.77 | ALDH1A1 (0.84) | RAB9APTPN2PTPN1PTPN6PTPN11 | |
| Hydrochloric Acid SCHEMBL31228945 | 0.77 | RAB9A (0.96) | RAB9APTPN2PTPN1PTPN6PTPN11 | |
| SCHEMBL7108252 | 0.77 | — | — | |
| SCHEMBL3483318 | 0.77 | — | — | |
| SCHEMBL1520253 | 0.77 | KMT2A (0.67) | RAB9APTPN2PTPN1PTPN6PTPN11 | |
| SCHEMBL9538774 | 0.76 | RAB9A (0.69) | RAB9APTPN2PTPN1PTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-07-14 | — | — | US | claimed |
| US-20110118127-A1 | MARKER GENES FOR SCREENING OF DRUG-INDUCED TOXICITY IN HUMAN CELLS AND SCREENING METHOD USING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-19 | — | — | US | claimed |
| EP-1226238-A2 | METHOD FOR CREATING DIVERGENT POPULATIONS OF NUCLEIC ACID MOLECULES AND PROTEINS | Cytos Biotechnology AG (CH) | 2002-07-31 | — | — | EP | claimed |
| WO-2001030989-A2 | METHOD FOR CREATING DIVERGENT POPULATIONS OF NUCLEIC ACID MOLECULES AND PROTEINS | CYTOS BIOTECHNOLOGY AG (US) | 2001-05-03 | — | — | WO | claimed |
| EP-4219735-B1 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | ABBOTT DIABETES CARE (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250312524-A1 | METHODS OF AMELIORATION OF CEREBROSPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR | ENCLEAR THERAPIES, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12350416-B2 | Methods of amelioration of cerebrospinal fluid and devices and systems therefor | ENCLEAR THERAPIES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-12331108-B2 | Antibodies with functional domains in the elbow region between variable and constant domain | INSTITUTE FOR RESEARCH IN BIOMEDICINE (CH) | 2025-06-17 | — | — | US | disclosed |
| EP-4538692-A2 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | Abbott Diabetes Care (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4219735-A1 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | Abbott Diabetes Care (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116059379-A | Compositions and methods utilizing STAT1/3 inhibitors and oncolytic herpes viruses | 复诺健生物科技加拿大有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-3645733-B1 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | ABBOTT DIABETES CARE (US) | 2023-04-26 | — | — | EP | disclosed |
| US-4569842-A | ANTIINFLAMMATORY, -TUMOR, PYRETICS-LIPEMIC AGENTS; ANALGESICS; HYPOGLYCEMIC AND HYPOTENSIVE AGENTS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-02-11 | — | — | US | disclosed |
| US-4559327-A | HYPOGLYLCEMIC, ANTIINFLAMMORY AGENTS; HYPERLIPEMIA, ANTIPYRETICS, ANTITUMOR AGENTS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-12-17 | — | — | US | disclosed |
| US-4555505-A | Method for the treatment of hyperglycemia using p-aminobenzoate-N-L-rhamnoside | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-11-26 | — | — | US | disclosed |
| US-4440757-A | SUGAR SUBSTITUTED AMINOBENZOIC ACIDS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-04-03 | — | — | US | disclosed |
| US-4322408-A | HYPOTENSIVE, HYPOGLYCEMIC, ANTITUMOR, ANTILIPEMIC AND ANTIINFLAMMATORY AGENTS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-03-30 | — | — | US | disclosed |
| US-4322409-A | HYPOTENSIVE, HYPOGLYCEMIC, ANTITUMOR, ANTILIPEMIC AND ANTIINFLAMMATORY AGENTS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-03-30 | — | — | US | disclosed |
| US-4315921-A | TREATMENT OF HYDERTENSION | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-02-16 | — | — | US | disclosed |
| US-4313939-A | Pharmaceutical composition containing para-aminobenzoic acid-N-L-rhamnoside as an active ingredient | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | RAB9A 1872/4885PTPN2 1906/4885PTPN1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.